The objective of this study was to compare tuberculosis (TB) screening results before and after implementation of a stratified testing strategy screening pilot study, incorporating interferon gamma release assay (IGRA) and tuberculin skin test (TST), based on country of origin. In 2015, the Washington State Department of Corrections began screening people born outside of the United States for TB with IGRA, while U.S.-born people continued screening by TST. Of 405 (75%) foreign-born men screened with IGRA, 403 had valid test results and IGRA screening positivity was 10.4% (N = 42). In contrast, among 5,940 primarily U.S-born men screened with TST, 24 (0.4%) were positive. Overall positivity was 1.05%, similar to TST-only positivity in 2013 (1.05%) and 2014 (0.85%). Incorporating IGRA screening among foreign-born persons was feasible in this state prison system.
CampbellJ. R., ChenW., JohnstonJ., CookV., ElwoodK., KrotJ., & MarraF. (2015). Latent tuberculosis infection screening in immigrants to low-incidence countries: A meta-analysis. Molecular Diagnosis & Therapy, 19(2),107–117. https://doi.org/10.1007/s40291-015-0135-6
3.
CattamanchiA., SmithR., SteingartK. R., MetcalfeJ. Z., DateA., ColemanC., MarstonB. J., HuangL., HopewellP. C., & PaiM. (2011). Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: A systematic review and meta-analysis. Journal of Acquired Immune Deficiency Syndromes, 56(3),230–238. https://doi.org/10.1097/QAI.0b013e31820b07ab
4.
Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. (2006). Prevention and control of tuberculosis in correctional and detention facilities: Recommendations from CDC. Endorsed by the Advisory Council for the Elimination of Tuberculosis, the National Commission on Correctional Health Care, and the American Correctional Association. MMWR. Morbidity and Mortality Weekly Report. Recommendations and Reports, 55(RR-9),1–44.
5.
De KeyserE., De KeyserF., & De BaetsF. (2014). Tuberculin skin test versus interferon-gamma release assays for the diagnosis of tuberculosis infection. Acta Clinica Belgica, 69(5),358–366. https://doi.org/10.1179/2295333714Y.0000000043
6.
DewanP.K., GrinsdaleJ., LiskaS. W, ongE., FallstadR., & KawamuraL. M. (2006). Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infect Dis 6, 47. https://doi.org/10.1186/1471-2334-6-47
7.
Diagnostic Standards and Classification of Tuberculosis in Adults and Children. (2000). This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. American Journal of Respiratory and Critical Care Medicine, 161(4 Pt 1),1376–1395. https://doi.org/10.1164/ajrccm.161.4.16141
8.
DielR., LoddenkemperR., Meywald-WalterK., GottschalkR., & NienhausA. (2009). Comparative performance of tuberculin skin test, QuantiFERON-TB-Gold In Tube assay, and T-Spot.TB test in contact investigations for tuberculosis. Chest, 135(4),1010–1018. https://doi.org/10.1378/chest.08-2048
9.
DielR., LoddenkemperR., & NienhausA. (2010). Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: A metaanalysis. Chest, 137(4),952–968. https://doi.org/10.1378/chest.09-2350
10.
DoanT. N., EisenD. P., RoseM. T., SlackA., StearnesG., & McBrydeE. S. (2017). Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: A latent-class analysis. PLoS One, 12(11), e0188631. https://doi.org/10.1371/journal.pone.0188631
11.
GrinsdaleJ. A., HoC. S., BanouvongH., & KawamuraL. M. (2011). Programmatic impact of using QuantiFERON®-TB Gold in routine contact investigation activities. International Journal of Tuberculosis and Lung Disease, 15(12),1614–1620. https://doi.org/10.5588/ijtld.11.0102
12.
GrinsdaleJ. A., IslamS., TranO. C., HoC. S., KawamuraL. M., & HigashiJ. M. (2016). Interferon-gamma release assays and pediatric public health tuberculosis screening: The San Francisco program experience 2005 to 2008. Journal of the Pediatric Infectious Diseases Society, 5(2),122–130. https://doi.org/10.1093/jpids/piu119
13.
GudjónsdóttirM. J., KötzK., NielsenR. S., WilmarP., OlaussonS., WallmyrD., & TrollforsB. (2016). Relation between BCG vaccine scar and an interferon-gamma release assay in immigrant children with “positive” tuberculin skin test (≥10 mm). BMC Infectious Diseases, 16(1), 540. https://doi.org/10.1186/s12879-016-1872-9
14.
KikS. V., FrankenW. P., MensenM., CobelensF. G., KamphorstM., ArendS. M., ErkensC., GebhardA., BorgdorffM. W., & VerverS. (2010). Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. European Respiratory Journal, 35(6),1346–1353. https://doi.org/10.1183/09031936.00098509
LambertL. A., ArmstrongL. R., LobatoM. N., HoC., FranceA. M., & HaddadM. B. (2016). Tuberculosis in jails and prisons: United States, 2002–2013. American Journal of Public Health, 106(12),2231–2237. https://doi.org/10.2105/AJPH.2016.303423
17.
MachingaidzeS., WiysongeC. S., Gonzalez-AnguloY., HatherillM., MoyoS., HanekomW., & MahomedH. (2011). The utility of an interferon gamma release assay for diagnosis of latent tuberculosis infection and disease in children: A systematic review and meta-analysis. Pediatric Infectious Disease Journal, 30(8),694–700. https://doi.org/10.1097/INF.0b013e318214b915
18.
MacIntyreC. R., KendigN., KummerL., BiragoS., & GrahamN. M. (1997). Impact of tuberculosis control measures and crowding on the incidence of tuberculous infection in Maryland prisons. Clinical Infectious Diseases, 24(6),1060–1067. https://doi.org/10.1086/513632
19.
MacNeilJ. R., LobatoM. N., & MooreM. (2005). An unanswered health disparity: Tuberculosis among correctional inmates, 1993 through 2003. American Journal of Public Health, 95(10),1800–1805. https://doi.org/10.2105/AJPH.2004.055442
20.
MancusoJ. D., ModyR. M., OlsenC. H., HarrisonL. H., SantoshamM., & AronsonN. E. (2017). The long-term effect of bacille Calmette-Guérin vaccination on tuberculin skin testing: A 55-year follow-up study. Chest, 152(2),282–294. https://doi.org/10.1016/j.chest.2017.01.001
21.
MenziesD. (2000). What does tuberculin reactivity after bacille Calmette-Guérin vaccination tell us? Clinical Infectious Diseases, 31(Suppl 3), S71–S74. https://doi.org/10.1086/314075
22.
MiramontesR., HillA. N., Yelk WoodruffR. S., LambertL. A., NavinT. R., CastroK. G., & LoBueP. A. (2015). Tuberculosis infection in the United States: Prevalence estimates from the National Health and Nutrition Examination Survey, 2011–2012. PLoS One, 10(11), e0140881. https://doi.org/10.1371/journal.pone.0140881
23.
NijhawanA. E., IrohP. A., BrownL. S., WinetskyD., & PorsaE. (2016). Cost analysis of tuberculin skin test and the QuantiFERON-TB Gold In-tube test for tuberculosis screening in a correctional setting in Dallas, Texas, USA. BMC Infectious Diseases, 16(1), 564. https://doi.org/10.1186/s12879-016-1901-8
24.
PaiM., ZwerlingA., & MenziesD. (2008). Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: An update. Annals of Internal Medicine, 149(3),177–184. https://doi.org/10.7326/0003-4819-149-3-200808050-00241
25.
PorsaE., ChengL., & GravissE. A. (2007). Comparison of an ESAT-6/CFP-10 peptide-based enzyme-linked immunospot assay to a tuberculin skin test for screening of a population at moderate risk of contracting tuberculosis. Clinical and Vaccine Immunology, 14(6),714–719. https://doi.org/10.1128/CVI.00073-07
26.
SchwartzI. S., BachP. J., RoscoeB., MajuryA., HopmanW. M., EllisE., GarrahanT., SmithJ., BarkleyR., PanaroL., JamiesonF., FroatsC., GemmillI., & WobeserW. L. (2014). Interferon-gamma release assays piloted as a latent tuberculous infection screening tool in Canadian federal inmates. International Journal of Tuberculosis and Lung Disease, 18(7),787–792. https://doi.org/10.5588/ijtld.13.0816
27.
StennisN. L., TrieuL., AhujaS. D., & HarrisT. G. (2014). Estimated prevalence of tuberculosis infection among a New York City clinic population using interferon-gamma release assays. Open Forum Infectious Diseases, 1(2), ofu047. https://doi.org/10.1093/ofid/ofu047
28.
StewartR. J., TsangC. A., PrattR. H., PriceS. F., & LangerA. J. (2018). Tuberculosis—United States, 2017. Morbidity and Mortality Weekly Report, 67(11),317–323. https://doi.org/10.15585/mmwr.mm6711a2
Wrighton-SmithP., SneedL., HumphreyF., TaoX., & BernackiE. (2012). Screening health care workers with interferon-γ release assay versus tuberculin skin test: Impact on costs and adherence to testing (the SWITCH study). Journal of Occupational and Environmental Medicine, 54(7),806–815. https://doi.org/10.1097/JOM.0b013e318254620f
